Survey - MnO_CA-LRTIMCI Registration NumberFULL NAME (As in your Pancard)EmailPhone/MobileCityStateSpecialityBank DetailsAccount Holder NameA/c NumberIFSC CodeUpload Cancelled Cheque (Max Size - 2 MB)Choose File Pancard NumberUpload Pancard Details (Max Size - 2 MB)Choose File EMPIRICAL ANTIBIOTIC SELECTION IN CA-LRTIs1. In your outpatient practice, what proportion of adult CA-LRTI (CAP/acute bronchitis with bacterial features) cases receive empirical antibiotics at the first visit itself, without awaiting culture/sensitivity? Less than 25% 25-50% 51-75% More than 75%2. For a previously healthy adult with mild-to-moderate CAP (CURB-65 0-1) managed as outpatient, which antibiotic class is your default first choice? Beta-lactam (amoxicillin/amox-clav) Oral third-generation cephalosporin Macrolide (azithromycin/clarithromycin) Respiratory fluoroquinolone3. Which single factor most influences your empirical choice in a treatment-naive CALRTI patient? Local resistance/antibiogram trends Patient compliance (dosing frequency, tolerability) Cost to patient Prior antibiotic exposure history4. In patients with CA-LRTI who have had antibiotic exposure in the preceding 3 months (raising resistance risk), what is your preferred step-up? Switch to oral third-gen cephalosporin Add beta-lactamase inhibitor combination Move to respiratory fluoroquinolone Refer for injectable therapy/admission5. What duration of oral antibiotic therapy do you typically prescribe for uncomplicated outpatient CA-LRTI? 3-5 days 5-7 days 7-10 days More than 10 days6. How often do comorbid patients (diabetes, COPD, elderly >65) change your antibiotic class choice versus a young healthy adult with the same LRTI presentation? Almost always — different class entirely Often — same class, higher potency/dose Occasionally Rarely — I treat the infection, not the demographic7. When a patient fails to improve clinically by day 3 on empirical oral therapy, what is your most common next step? Switch oral class (e.g., to an oral cephalosporin) Add a second agent Refer for chest imaging/investigation Refer/admit for parenteral therapy8. How would you rate your confidence in current oral third-generation cephalosporins (e.g., cefpodoxime) achieving adequate respiratory tissue penetration for outpatient CA-LRTI coverage? High confidence, first-line-worthy Moderate — reserve for step-up/failure cases Low — prefer injectable route for this class Not routinely considered in my LRTI protocol9. Which best describes your awareness/use of Indian antimicrobial stewardship guidance (ICMR AMR guidelines / NCCP treatment algorithms) in shaping empirical choice for CA-LRTI? Actively follow and reference them Aware, but rely more on clinical experience Aware, not actively applied Not familiar with specific Indian guidance documents10. Case vignette: 45-year-old, no comorbidities, fever + productive cough + focal crepitations, CURB-65 = 0, no antibiotic exposure in past 3 months. Which is your empirical choice? Amoxicillin/amox-clavulanate Oral third-generation cephalosporin Azithromycin Respiratory fluoroquinolone I have read and agree to the Terms and Conditions .Submit Form